Selected publications

(*(co-)first author, #(co-)corresponding author)
Full publications can be accessed at  Google Scholar
  1. Luo M, Liu Y, Hermida LC, Gertz, EM, Zhang Z, Li Q, Diao L, Ruppin E, and Han L#, 2022. Race is a key determinant of the human intratumor microbiome. Cancer cell, 40(9), pp.901-902.
  2. Liu Y#,  Han L# (2022). TRUST4 Interrogates the Immune Receptor Repertoire in Oncology and Immunotherapy. Cancer Immunology Research, OF1-OF1.
  3. Jing Y*, Yang J*, Johnson DB#, Moslehi JJ#, Han L#. Harnessing big data to characterize immune-related adverse events. Nature Reviews Clinical Oncology 19269–280 (2022). 
  4. Jing Y*, Chen X*, Li K, Liu Y, Zhang Z, Chen Y, Liu Y, Wang Y, Lin SH, Diao L, Wang J, Lou Y, Johnson DB, Chen X#, Liu H#, Han L#. Association of antibiotic treatment with immune-related adverse events in cancer patients receiving immunotherapy. Journal of Immunotherapy of Cancer (In press)
  5. Zhang Z#,*, Luo M*, Li Q, Liu Y, Lussier C, Zhang J, Ye Y, Guo AY#, Han L#. Genetic, pharmacogenomic, and immune landscapes of enhancer RNAs across human cancers. Cancer Research (In press)
  6. Ye Y*, Zhang Y*, Yang N*, Gao Q*, Ding X, Kuang X, Bao R, Zhang Z, Sun C, Zhou B, Wang L, Hu Q, Lin C, Gao J, Lou Y, Lin SH, Diao L, Liu H#, Chen X#, Mills GB#, Han L#. Profiling of immune features to predict immunotherapy efficacy. The Innovation, 2021
  7. Jing Y#,*, Liu Y*, Li Q, Ye Y, Diao L, Huang Y, Zhou Y, Green MR, Mills GB, Han L#. Expression of chimeric antigen receptor therapy targets detected by single-cell sequencing of normal cells may contribute to off-tumor toxicity. Cancer Cell, 2021. PMID: 34678153
  8. Zhang Z, Han L#. Circular RNAs sequenced at last. Nature Biotechnology. 2021. PMID: 33948001
  9. Correa S#, Han L#. Career pathways, part 4. Nature Metabolism. 2021, 3: 446-448. PMID: 33824514
  10. Ruan H#, Li Q, Liu Y, Liu Y, Lussier C, Diao L, Han L#. GPEdit: the genetic and pharmacogenomic landscape of A-to-I RNA editing in cancers. Nucleic Acids Research. 2021. gkab810. PMID: 34534336
  11. Jing Y*, Zhang Y*, Wang J*, Li K*, Chen X, Heng J, Gao Q, Ye Y, Zhang Z, Liu Y, Lou Y, Lin SH, Diao L, Liu H#, Chen X#, Mills GB#, Han L#. Association between sex and immune-related adverse events during immune checkpoint inhibitor therapy. Journal of National Cancer Institute, 2021. PMID:33705549
  12. Zhang Z, Jing , Ye Y, Chen Z, Jing Y, Li S, Hong W, Ruan H, Liu Y, Hu Q, Wang J, Li W, Lin C, Diao L#, Zhou Y#, Han L#.  Characterization of the dual functional effects of heat shock proteins (HSPs) in cancer hallmarks to aid development of HSP inhibitors. Genome Medicine, 2020, 12: 101. PMID: 33225964
  13.  Zhang Z#, Hong W, Ruan H, Jing Y, Li S, Liu Y, Wang J, Li W, Diao L#, Han L#: HeRA: an atlas of enhancer RNAs across human tissues. Nucleic Acids Research, 2020, gkaa940, PMID: 33119754
  14. Jing Y, Liu J, Ye Y, Pan L, Deng H, Wang Y, Yang Y, Diao L, Lin SH, Mills GB, Zhuang G#, Xue X#, Han L#. Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy. Nature Communications, 2020, 11: 4946, PMID: 33009409
  15. Liu Y, Ruan H, Li S, Ye Y, Hong W, Gong J, Zhang Z, Jing Y, Zhang X#, Diao L#, Han L#. The genetic and pharmacogenomic landscape of snoRNAs in human cancer. Molecular Cancer, 2020, 19: 108, PMID: 32576192
  16. Ye Y, Jing Y, Li L, Mills GB, Diao L#, Liu H#, Han L#. Sex-associated molecular differences for cancer immunotherapy. Nature Communications, 2020, 11: 1779, PMID: 32286310
  17. Ye Y, Zhang Z, Liu Y, Diao L#, Han L#: A Multi-Omics Perspective of Quantitative Trait Loci in Precision Medicine. Trends in Genetics, 2020, 36: 318-336, PMID: 32294413 (Feature review)
  18. Li S#, Zhang Z, Han L#: 3D Spheroids Propel Tumor Characterization. Trends in Cancer, 2020, PMID: 32423684
  19. Zhang Z, Lee JH, Ruan H, Ye Y, Krakowiak J, Hu Q, Xiang Y, Gong J, Zhou B, Wang L, Lin C, Diao L, Mills GB, Li W#, Han L#. Transcriptional landscape and clinical utility of enhancer RNAs for eRNA-targeted therapy in cancer. Nature Communications, 2019, 10: 4562. PMID: 31594934
  20. Li S, Zhang Z, Han L#: Molecular Treasures of Cancer Cell Lines. Trends in Molecular Medicine, 2019 PMID: 31255475
  21. Li S, Han L: Circular RNAs as promising biomarkers in cancer: detection, function, and beyond. Genome Medicine, 2019, 11:15. PMID:
    30894216
  22. Zhang Z, Lee JH, Ruan H, Ye Y, Krakowiak J, Hu Q, Xiang Y, Gong J, Zhou B, Wang L, Lin C, Diao L, Mills GB, Li W#, Han L#. Transcriptional landscape and clinical utility of enhancer RNAs for eRNA-targeted therapy in cancer. Nature Communications, 2019, 10: 4562. PMID: 31594934
  23. Ruan H, Xiang Y, Ko J, Li S, Jing Y, Zhu X, Ye Y, Zhang Z, Mills T, Feng J, Liu CJ, Jing J, Cao J, Zhou B, Wang L, Zhou Y, Lin C, Guo AY, Chen X, Diao L, Li W, Chen Z, He X, Mills GB, Blackburn MR, Han L#. Comprehensive characterization of circular RNAs in ~1000 human cancer cell lines. Genome Medicine, 2019, 11: 55. PMID: 31446897
  24. Hong W, Ruan H, Zhang Z, Ye Y, Liu Y, Li S, Jing Y, Zhang H, Diao L, Liang H, Han L#. APAatlas: decoding alternative polyadenylation across human tissues. Nucleic Acids Research. 2019. PMID: 31586392
  25. Ye Y, Hu Q, Chen H, Liang K, Yuan Y, Ruan H, Zhang Z, Song A, Zhang H, Liu L, Diao L, Lou Y, Zhou B, Wang L, Zhou S, Gao J, Jonasch E, Lin S, Xia Y, Lin C, Yang L#, Mills GB#, Liang H#, Han L#: Characterization of Hypoxia-associated Molecular Features to Aid Hypoxia-Targeted Therapy. Nature Metabolism, 2019, 1: 431-444. PMID: 31984309
  26. Hu Q, Ye Y, Chan LC, Liang K, Li Y, Evans K, Pan Y, Zhang Y, Xia W, Liu J, Gong J, Chatterjee S, Han L#, Lin C#, Yang L#: Oncogenic LncRNA Downregulates Cancer Cell Antigen Presentation and Intrinsic Tumor Suppression. Nature Immunology, 2019 PMID: 31160797
  27. Xiang Y, Ye Y, Zhang Z, Han L#: Maximizing the utility of cancer transcriptomic data. Trends in Cancer, 2018, 4:823-837. PMID: 30470304
  28. Gong J, Wan H, Mei S, Ruan H, Zhang Z, Liu C, Guo AY, Diao L#, Miao X#, Han L#: Pancan-meQTL: a database to systematically evaluate the effects of genetic variants on methylation in human cancer. Nucleic Acids Research, 2018, gky814
  29. Ye Y, Xiang Y, Ozguc FM, Kim Y, Liu CJ, Park PK, Hu Q, Diao L, Lou Y, Lin C, Guo AY, Zhou B, Wang L, Chen Z, Takahashi JS, Mills GB, Yoo SH, Han L#: The genomic landscape and pharmacogenomic interactions of clock genes in cancer chronotherapy. Cell Systems, 2018, 6: 314-328 
  30. Gong J, Li Y, Liu CJ, Xiang Y, Li C, Ye Y, Zhang Z, Hawke DH,  Park PK, Diao L, Putkey JA, Yang L, Guo AY#, Lin C#, Han L#: A pan-cancer analysis of the expresion and clinical relevance of small nucleolar RNA in human cancer. Cell Reports, 2017, 21: 1968-1981 
  31. Xiang Y, Ye Y, Lou Y, Yang Y, Cai C, Zhang Z, Mills T, Chen NY, Kim Y, Ozguc FM, Diao L, Karmouty-Quintana H, Xia Y, Blackburn M, Kellems R, Chen Z, Yoo SH, Shyu AB, Mills GB, Han L#: Comprehensive characterization of alternative polyadenylation in human cancer. Journal of the National Cancer Institute, 2017, djx223
  32. Gong J, Mei S, Liu C, Xiang  Y,Ye Y, Zhang Z, Feng J, Liu R, Diao L, Guo AY, Miao X, Han L#: PancanQTL: systematic identification of cis-eQTLs and trans-eQTLs in 33 cancer types. Nucleic Acids Research, 2017, gkx861
  33. Gong J, Liu C, Liu W, Xiang Y, Diao L, Guo AY#, Han L#: LNCediting: a database for functional effects of RNA editing in lncRNAs. Nucleic Acid Research. 2016, gkw835 
  34. Han L, Diao L, Yu S, Xu X, Li J, Zhang R, Yang Y , Werner HM, Eterovic KA, Yuan Y, Li J, Nair N, Minelli R, Tsang Y, Cheung LW, Jeong KJ, Roszik J, Ju Z, Woodman S, Lu Y, Scott KL, Li JB, Mills GB, Liang H: The genomic landscape and clinical relevance of A-to-I RNA editing in human cancers. Cancer Cell, 2015, 28: 515-528.